We are investigating whether intranasal oxytocin can enhance social skills and functioning in individuals with schizophrenia spectrum disorders. This study compares oxytocin to a placebo alongside standard psychosocial treatment.
We are studying a new treatment for patients with advanced or metastatic solid tumors to see how well it works and its safety when used alone or with other cancer drugs.
We are testing a new treatment called AVB-101 for individuals with frontotemporal dementia due to specific genetic mutations. The study aims to assess its safety and early effects on symptoms.
We are investigating whether sotagliflozin can improve kidney oxygen levels in people with type 1 diabetes and chronic kidney disease. This study aims to understand its effects over three months of treatment.
We are testing a new radioactive treatment for patients with metastatic FAP-positive solid tumors. The study looks at its safety and early signs of effectiveness, both alone and with another therapy.
We are comparing two laxatives to see which one better prevents constipation in patients with advanced cancer starting opioid pain treatment. This study will also assess quality of life and side effects.
We are studying the safety and effectiveness of the ILUVIEN® eye implant in children aged 6 to under 18 with recurrent non-infectious uveitis. This research aims to understand how well the implant works and any possible side effects.
We are studying the safety and effectiveness of volrustomig combined with chemotherapy and other drugs for patients with advanced or metastatic non-small cell lung cancer. This research aims to find better treatment options for this condition.
We are studying how two PET tracers relate to T cell changes in cancer patients before surgery. This research may help us understand T cell activation and its impact on tumor response.
We are investigating whether adding extra chemotherapy cycles helps high-risk patients with resectable soft-tissue sarcomas have better outcomes after surgery. This study compares the effects of different chemotherapy regimens on survival rates.
We are studying a new treatment combining atezolizumab, EIK10001, and radiation for patients with advanced solid tumors like pancreatic cancer and triple-negative breast cancer. This trial aims to evaluate how well this combination works in controlling cancer.
We are investigating the effects of a combination of pembrolizumab and cabozantinib in patients with advanced sarcomas. The goal is to see if this treatment can help prevent disease progression and improve overall outcomes.
We are studying a new treatment combining Bintrafusp alfa with doxorubicin for patients with advanced sarcoma. The goal is to see if this combination improves tumor response and safety compared to standard treatments.
We are comparing a new treatment called RO7198457 to watchful waiting in patients with high-risk, resected Stage II and Stage III colorectal cancer. The goal is to see if the new treatment can help prevent cancer recurrence better than simply monitoring.
We are testing a new medication for people with moderate to severe tardive dyskinesia to see how safe it is for long-term use. The study will also look at its long-term effects on managing symptoms.
We are testing a new medication for adults with solid tumors or lymphoma that have not responded to other treatments. This study aims to evaluate its safety and potential effectiveness.
We are exploring the use of stem cells from fat tissue to treat primary progressive multiple sclerosis. This study aims to assess the safety and potential benefits of this new approach.
We are investigating whether a new treatment combining pozelimab with cemdisiran helps slow the progression of geographic atrophy in adults. This study aims to understand its effects on vision and safety compared to cemdisiran alone.
We are testing a new imaging method to see how well immune checkpoint inhibitor therapy works in patients with advanced melanoma. This study aims to improve response evaluation during treatment.
We are studying whether an intermittent treatment of Panitumumab with FOLFIRI is as effective as continuous treatment for patients with metastatic left-sided colorectal cancer. The trial also aims to assess safety and quality of life for participants.